×
About 19,215 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  8,889 results

Clinical analysis of patients with primary and secondary extranodal natural killer/T-ce...
https://doi.org/10.1002/hon.2894
Hematological Oncology; Li X, Yu H et. al.

Jun 1st, 2021 - Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is n...

A Review and Update with Perspective of Evidence that the Herbicide Glyphosate (Roundup...
https://doi.org/10.1016/j.clml.2021.04.009
Clinical Lymphoma, Myeloma & Leukemia; Weisenburger DD

May 30th, 2021 - Glyphosate-based formulations (GBFs), such as Roundup, are the most heavily used herbicides in the world. In 2015, the International Agency for Research on Cancer (IARC) concluded that glyphosate and GBFs are probably carcinogenic to humans (group...

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and ...
https://doi.org/10.1016/j.leukres.2021.106615
Leukemia Research; Sharda E, Patel RS et. al.

May 30th, 2021 - Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage o...

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open...
https://doi.org/10.1016/S2352-3026(21)00103-4
The Lancet. Haematology; Hamadani M, Collins GP et. al.

May 28th, 2021 - Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. We aimed to evaluate camidanlumab tesirine, an anti-CD25 antibody-drug conjugate, in this patient population. This was...

Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design a...
https://doi.org/10.1007/s12325-021-01738-2 10.1182/blood.V89.11.3909 10.1182/blood-2005-01-0016 10.1016/S0140-6736(10)62175-7 10.1200/JCO.2005.04.503 10.1200/JCO.2005.03.1674 10.1200/JCO.2006.06.4618 10.1200/JCO.2007.13.5376 10.3324/haematol.2012.082412 10.1093/jnci/djk152 10.1200/JCO.2008.17.1561 10.1200/JCO.19.01073 10.1016/j.ejca.2017.01.021 10.1007/s12325-016-0451-1 10.1182/blood-2013-05-504043 10.1200/JCO.2017.76.8960 10.1056/NEJMoa1614598 10.1002/cam4.1217 10.1200/JCO.2018.77.9124 10.1007/s10549-019-05262-4 10.2147/OTT.S82365 10.1001/jamainternmed.2013.3037 10.1208/s12248-017-0056-x 10.1093/jnci/djp369 10.1200/JCO.2006.09.2403 10.1200/JCO.2013.54.8800 10.1182/bloodadvances.2020002858 10.1200/JCO.19.02019 10.1080/10543406.2015.1092033 10.1001/jama.2013.285063 10.1200/JCO.2016.70.2217 10.1016/j.jacc.2015.10.014 10.1182/blood-2018-99-115167 10.3324/haematol.2018.209015 10.1182/bloodadvances.2020003797 10.1200/JCO.2016.70.8651 10.1038/bmt.2016.222 10.1182/blood-2015-08-634816 10.1038/s41375-019-0559-9 10.1016/j.jmoldx.2018.03.005 10.1042/BSR20180974 10.1177/2040620713480522 10.1182/blood.V128.22.613.613 10.1200/JCO.2018.78.5246 10.4084/mjhid.2017.029 10.1200/JCO.2012.43.0934 10.1093/annonc/mdt562 10.1200/JCO.2011.35.0736 10.1016/S1470-2045(18)30618-1 10.1056/NEJMoa1805104 10.1016/S0140-6736(12)61763-2 10.1200/JCO.2018.79.3083 10.1200/JCO.2008.21.3991 10.1002/ajh.25973 10.1182/blood-2017-11-816405 10.1016/S1470-2045(18)30102-5 10.1016/S1470-2045(15)00169-2 10.1182/blood-2019-130208 10.1182/blood-2008-04-153189 10.1200/JCO.2012.45.0866
Advances in Therapy; Bachy E, Rufibach K et. al.

May 27th, 2021 - Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma worldwide. Improved survival outcomes with rituximab-based therapy in clinical trials led to the establishment of rituximab-based immunochemotherapy as standard of...

see more →

Guidelines  59 results

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated th...

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, ...

see more →

Drugs  99 results see all →

Clinicaltrials.gov  9,535 results

Clinical analysis of patients with primary and secondary extranodal natural killer/T-ce...
https://doi.org/10.1002/hon.2894
Hematological Oncology; Li X, Yu H et. al.

Jun 1st, 2021 - Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is n...

A Review and Update with Perspective of Evidence that the Herbicide Glyphosate (Roundup...
https://doi.org/10.1016/j.clml.2021.04.009
Clinical Lymphoma, Myeloma & Leukemia; Weisenburger DD

May 30th, 2021 - Glyphosate-based formulations (GBFs), such as Roundup, are the most heavily used herbicides in the world. In 2015, the International Agency for Research on Cancer (IARC) concluded that glyphosate and GBFs are probably carcinogenic to humans (group...

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and ...
https://doi.org/10.1016/j.leukres.2021.106615
Leukemia Research; Sharda E, Patel RS et. al.

May 30th, 2021 - Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage o...

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open...
https://doi.org/10.1016/S2352-3026(21)00103-4
The Lancet. Haematology; Hamadani M, Collins GP et. al.

May 28th, 2021 - Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. We aimed to evaluate camidanlumab tesirine, an anti-CD25 antibody-drug conjugate, in this patient population. This was...

Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design a...
https://doi.org/10.1007/s12325-021-01738-2 10.1182/blood.V89.11.3909 10.1182/blood-2005-01-0016 10.1016/S0140-6736(10)62175-7 10.1200/JCO.2005.04.503 10.1200/JCO.2005.03.1674 10.1200/JCO.2006.06.4618 10.1200/JCO.2007.13.5376 10.3324/haematol.2012.082412 10.1093/jnci/djk152 10.1200/JCO.2008.17.1561 10.1200/JCO.19.01073 10.1016/j.ejca.2017.01.021 10.1007/s12325-016-0451-1 10.1182/blood-2013-05-504043 10.1200/JCO.2017.76.8960 10.1056/NEJMoa1614598 10.1002/cam4.1217 10.1200/JCO.2018.77.9124 10.1007/s10549-019-05262-4 10.2147/OTT.S82365 10.1001/jamainternmed.2013.3037 10.1208/s12248-017-0056-x 10.1093/jnci/djp369 10.1200/JCO.2006.09.2403 10.1200/JCO.2013.54.8800 10.1182/bloodadvances.2020002858 10.1200/JCO.19.02019 10.1080/10543406.2015.1092033 10.1001/jama.2013.285063 10.1200/JCO.2016.70.2217 10.1016/j.jacc.2015.10.014 10.1182/blood-2018-99-115167 10.3324/haematol.2018.209015 10.1182/bloodadvances.2020003797 10.1200/JCO.2016.70.8651 10.1038/bmt.2016.222 10.1182/blood-2015-08-634816 10.1038/s41375-019-0559-9 10.1016/j.jmoldx.2018.03.005 10.1042/BSR20180974 10.1177/2040620713480522 10.1182/blood.V128.22.613.613 10.1200/JCO.2018.78.5246 10.4084/mjhid.2017.029 10.1200/JCO.2012.43.0934 10.1093/annonc/mdt562 10.1200/JCO.2011.35.0736 10.1016/S1470-2045(18)30618-1 10.1056/NEJMoa1805104 10.1016/S0140-6736(12)61763-2 10.1200/JCO.2018.79.3083 10.1200/JCO.2008.21.3991 10.1002/ajh.25973 10.1182/blood-2017-11-816405 10.1016/S1470-2045(18)30102-5 10.1016/S1470-2045(15)00169-2 10.1182/blood-2019-130208 10.1182/blood-2008-04-153189 10.1200/JCO.2012.45.0866
Advances in Therapy; Bachy E, Rufibach K et. al.

May 27th, 2021 - Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma worldwide. Improved survival outcomes with rituximab-based therapy in clinical trials led to the establishment of rituximab-based immunochemotherapy as standard of...

see more →

News  631 results

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 25th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

Combo Provides 'Broad Benefit' Across NHL Subtypes
https://www.medscape.com/viewarticle/949208

Apr 12th, 2021 - The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

see more →

Patient Education  2 results see all →